Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I trial of CK-0801 in patients with autoimmune diseases and inflammatory disorders

Trial Profile

A phase I trial of CK-0801 in patients with autoimmune diseases and inflammatory disorders

Planning
Phase of Trial: Phase I

Latest Information Update: 10 Jun 2018

At a glance

  • Drugs CK 0801 (Primary)
  • Indications Aplastic anaemia; Autoimmune disorders; Bone marrow disorders; Inflammation; Myelodysplastic syndromes; Myelofibrosis
  • Focus Adverse reactions
  • Sponsors Cellenkos
  • Most Recent Events

    • 10 Jun 2018 According to a Cellenkos Inc. media release,the United States Food and Drug Administration has cleared the Investigational New Drug (IND) application which allows for Cellenkosto proceed with a phase I clinical trial of CK0801
    • 10 Jun 2018 According to a Cellenkos Inc. media release, the company plans to initiate this trial in in the third quarter of 2018 at The University of Texas MD Anderson Cancer Center, Houston, Texas
    • 07 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top